Wolverine Asset Management’s CERo Therapeutics Warrants CEROW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-33,796
| Closed | -$449 | – | 1902 |
|
|
2025
Q3 | $449 | Hold |
33,796
| – | – | ﹤0.01% | 1539 |
|
|
2025
Q2 | $804 | Sell |
33,796
-10,000
| -23% | -$155 | ﹤0.01% | 1516 |
|
|
2025
Q1 | $635 | Hold |
43,796
| – | – | ﹤0.01% | 1474 |
|
|
2024
Q4 | $363 | Hold |
43,796
| – | – | ﹤0.01% | 1554 |
|
|
2024
Q3 | $223 | Hold |
43,796
| – | – | ﹤0.01% | 1595 |
|
|
2024
Q2 | $880 | Sell |
43,796
-20,317
| -32% | -$1.19K | ﹤0.01% | 1548 |
|
|
2024
Q1 | $4.37K | Sell |
64,113
-23,780
| -27% | -$1.45K | ﹤0.01% | 1400 |
|
|
2023
Q4 | $2.06K | Hold |
87,893
| – | – | ﹤0.01% | 1557 |
|
|
2023
Q3 | $6.29K | Hold |
87,893
| – | – | ﹤0.01% | 1534 |
|
|
2023
Q2 | $5.37K | Hold |
87,893
| – | – | ﹤0.01% | 1470 |
|
|
2023
Q1 | $3.52K | Hold |
87,893
| – | – | ﹤0.01% | 1588 |
|
|
2022
Q4 | $3.79K | Buy |
87,893
+7,204
| +9% | +$379 | ﹤0.01% | 1777 |
|
|
2022
Q3 | $6K | Hold |
80,689
| – | – | ﹤0.01% | 2118 |
|
|
2022
Q2 | $8K | Hold |
80,689
| – | – | ﹤0.01% | 2047 |
|
|
2022
Q1 | $17K | Hold |
80,689
| – | – | ﹤0.01% | 1799 |
|
|
2021
Q4 | $33K | Buy |
+80,689
| New | +$37.2K | ﹤0.01% | 1619 |
|
Other funds holding CEROW
Wolverine Asset Management's CEROW Position: Q4 2025 in Review
Wolverine Asset Management sold out of CERo Therapeutics Warrants (CEROW) in Q4 2025, closing a stake of 33,796 shares — an estimated $449 sold.
Wolverine Asset Management first reported a position in CEROW in Q4 2021 and held it in 16 quarters. The position peaked at $33K in Q4 2021. 1 fund tracked by Wall St. Rank holds CEROW as of Q4 2025.
- Wolverine Asset Management reported no remaining CERo Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
- Wolverine Asset Management sold 33,796 CERo Therapeutics Warrants shares in Q4 2025, an estimated $449.
- Wolverine Asset Management first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 16 quarters.
- Wolverine Asset Management's CERo Therapeutics Warrants position peaked at $33K in Q4 2021.
- 1 fund tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2025.
Based on Wolverine Asset Management's 13F filing for Q4 2025, filed 2 Feb 2026.